Urine cfDNA Test for Colon Cancer Screening
Colorectal Cancer Screening
DevelopmentActive
Key Facts
About JBS Science
JBS Science is a privately-held diagnostics company founded in 2008 and incorporated in 2011, headquartered in San Diego, CA. It has developed proprietary technologies for cfDNA isolation and sensitive qPCR assays, aiming to detect primary and recurrent cancers via a simple urine test. The company has been primarily funded through multiple NIH SBIR grants, including a significant $3 million Bridge Award from the NCI, and has established key collaborations and a licensing agreement for its isolation kits. Its current focus appears to be on liver cancer (HCC) screening, with data presented at major hepatology and oncology conferences.
View full company profileTherapeutic Areas
Other Colorectal Cancer Screening Drugs
| Drug | Company | Phase |
|---|---|---|
| Shield (ECLIPSE Study) | Guardant Health | FDA Approved |
| iFOB | Pangea Laboratory | Commercial |
| ColoHealth | New Day Diagnostics | Approved |
| CRC Screening Program | Polymedco | Commercial |
| SimpleScreen CRC | Freenome | Commercial (as LDT) |
| ColoScape™ / QuantiDNA™ | DiaCarta | Commercial |
| ColoSense | Geneoscopy | Approved |
| At-Home Colorectal Cancer Screening | SNT Biotech | Commercial |
| FIT System & Assay Development | Sentinel Diagnostics | Commercial |
| Next-Generation Cologuard® | Exact Sciences | Development |
| ColoAlert® | Mainz Biomed | Pivotal Trial |